ClinicalTrials.gg
RecruitingNCT07673029Updated Jun 29, 2026

A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

A Phase 3 interventional study of GQ1005 and T-DM1 in HER2-positive Breast Cancer, sponsored by GeneQuantum Healthcare (Suzhou) Co., Ltd.. Recruiting at 70 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by GeneQuantum Healthcare (Suzhou) Co., Ltd. · Phase 3, Interventional, and Treatment

How we know · 6 judgments

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Jan 2025, registered Jun 2026).
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
228
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 1,936 studies in Breast Neoplasms with a site in China — 871 open to participants now, 1,068 under way, 211 of them phase 3. Breast Neoplasms · China.

Planned enrollment
507th of 1,525
228 · median 120
Started
2025
with 237 others
Phase 3
332 of 1,936
121 open now
Primary completion
2027-01
later than 601 of 1,067 live
Registered
1,848th of 1,936
by date

Among the 1,936 studies in Breast Neoplasms with a site in China, this one is the 507th largest by planned enrollment of the 1,525 interventional ones that give a count, is one of 238 that started in 2025, is one of 332 in phase 3, reaches primary completion later than 601 of the 1,067 other live ones, and was the 1,848th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

871 of the 1,936 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

866 more — sign in →

All 871 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,575 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,936 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study is designed to compare efficacy and safety of GQ1005 versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer patients previously treated with trastuzumab and taxane.

Read the detailed description

This is a phase III, multicenter, open-label, randomized controlled study comparing GQ1005 with Trastuzumab Emtansine (T-DM1) in patients with HER2-positive unresectable or metastatic breast cancer previously treated with trastuzumab and taxane. Approximately 228 patients with unresectable or metastatic HER2-positive breast cancer will be randomized 1:1 to receive GQ1005 or T-DM1, respectively.

03

Conditions studied

  • HER2-positive Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female adults ≥ 18 years at the time of voluntary signing of .
  • confirmed unresectable or positive breast cancer previously treated with trastuzumab and taxane
  • (ECOG) performance status score is 0 or 1.
  • Presence of at least one according to v1.1
  • Expected survival time ≥ 12 weeks.
  • Patients must give informed consent to this study and voluntarily sign written informed consent form prior to the study NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Prior anti- ADC therapy.
  • Previous history of interstitial lung disease/noninfectious pneumonitis/radiation pneumonitis requiring therapy.
  • Known serious to the active ingredients of the study drug, inactive ingredients in the formulation, or other antibody drugs.
  • Multiple primary within 3 years, except for adequately resected non-melanoma skin cancer, curatively treated in situ tumor, or contralateral breast cancer
  • Uncontrolled infection requiring intravenous antibiotics, antiviral or antifungal agents, disease requiring treatment, uncontrolled diabetes, hypertension, or other systemic disease that makes compliance with study procedures difficult
  • Unrecovered toxicity from prior anticancer therapy, defined as toxicity (except for alopecia) not recovered to ≤Grade 1 ( v5.0) or baseline.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
228 participants (estimated)

Study arms

  • Experimental
    GQ1005

    GQ1005 will be administered intravenously every 21 days.

    Drug: GQ1005

  • Experimental
    T-DM1

    T-DM1 will be administered intravenously every 21 days.

    Drug: T-DM1

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessment per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    Time frame: Up to approximately 24 months

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: Up to approximately 24 months

  2. Progression Free Survival (PFS) by Investigator assessment per RECIST 1.1

    Time frame: Up to approximately 24 months

  3. Objective response rate (ORR) by BICR and investigator assessment per RECIST 1.1

    Time frame: Up to approximately 24 months

  4. Duration of response (DoR) by BICR and investigator assessment per RECIST 1.1

    Time frame: Up to approximately 24 months

  5. Disease Control Rate (DCR) by BICR and investigator assessment per RECIST 1.1

    Time frame: Up to approximately 24 months

  6. Adverse events:Number and percentage of patients who report serious adverse events (SAEs), treatment-emergent adverse events (TEAEs), TEAEs leading to study drug discontinuation, adverse events of special interest (AESIs) (graded according to the Nationa

    Time frame: Up to approximately 24 months

  7. PK parameters:Plasma concentrations of GQ1005 ADC, total anti-HER2 antibody and free toxin DXd at each time point

    Time frame: Up to approximately 24 months

  8. Anti-drug antibodies (ADA):Number and percentage of patients who develop anti-drug antibody (ADA).

    Time frame: Up to approximately 24 months

  9. Quality of Life Assessment:Change in Health-Related Quality of Life Assessed by EQ-5D-5L

    Change from baseline in EQ-5D-5L health state utility index score and Visual Analogue Scale (VAS) score. VAS score range from 0-100, higher scores indicate better health status.

    Time frame: Up to approximately 24 months

  10. Quality of Life Assessment:Change in Health-Related Quality of Life Assessed by European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) - C30

    Change from baseline in the functioning/symptom/global quality of life (QoL) subscales of EORTC QLQ-C30. Scale scores range from 0-100. For functioning and global QoL scales, higher scores indicate better functioning or global health status. For symptom scales, higher scores indicate greater symptom burden.

    Time frame: Up to approximately 24 months

  11. Quality of Life Assessment:Change in Health-Related Quality of Life Assessed by EORTC QLQ-BR45

    Change from baseline in the functioning/symptom subscales of EORTC QLQ-BR45. Scale scores range from 0-100. For functioning scales, higher scores indicate better functioning. For symptom scales, higher scores indicate greater symptom burden.

    Time frame: Up to approximately 24 months

07

Study locations

70 of 70 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jan 2027, 23 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 23 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2026
First posted
Jun 29, 2026
StartActual
Jan 10, 2025
Primary completionEst.
Jan 9, 2027
CompletionEst.
Jan 9, 2028
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07673029
Lead sponsor
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Responsible party
Sponsor
First posted
Jun 29, 2026
Start date
Jan 10, 2025
Primary completion
Jan 9, 2027 (estimated)
Completion
Jan 9, 2028 (estimated)
Last update
Jun 29, 2026

Study contacts

Zhenxing Yang
Contact
yangzx@genequantum.com
+86 13801896162
Zefei Jiang, M.D.
principal investigator · The Fifth Medical Center of the Chinese People's Liberation Army General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion